An independent Business Case Study into the commercial viability of a small scale Mammalian cell production facility was commissioned by the former Department of Industry, Tourism and Resources (DITR) and undertaken by the Zektin Group in collaboration with Innovation Dynamics, Seer Pharma and the Australian Institute for Bioengineering and Nanotechnology. The Business Case concluded that:
- there is a niche opportunity for Australia to service global and local demand for small scale mammalian cell production;
- up to $35 million of mammalian cell based clinical development work is sent to offshore Contract Manufacturing Organisations (CMOs) each year because of a lack of capability in Australia;
- a facility could reasonably earn between $32 million and $62 million of revenue a year, but would need to attract overseas revenue to be viable;
- an alliance with a multinational-pharmaceutical company (by way of supply contracts) and/or with an established CMO (as operator) is regarded as pivotal to the commercial success of such a facility; and
- the facility had positive net present values and reasonable internal rates of return (up to 34% under the best case scenario), especially with a $10 million grant.
The Business Case study can be found below. Applicant(s) were requested to undertake their own analysis and not rely on indicative information provided by the Business Case study commissioned by the former Department of Industry, Tourism and Resources.
Return to Mammalian Cell Production Facility main page.
For further information, please contact:
|
Peter Chesworth
Tel: 02 6213 6058 |
| Email |
Pharmaceuticals and Medical Technology Section
Department of Innovation, Industry, Science and Research
GPO Box 9839
CANBERRA ACT 2601
Tel: 02 6213 6597
Email